Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Assets (2020 - 2025)

Historic Assets for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to $196.6 million.

  • Treace Medical Concepts' Assets fell 767.08% to $196.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.6 million, marking a year-over-year decrease of 767.08%. This contributed to the annual value of $217.1 million for FY2024, which is 1381.98% down from last year.
  • Per Treace Medical Concepts' latest filing, its Assets stood at $196.6 million for Q3 2025, which was down 767.08% from $206.4 million recorded in Q2 2025.
  • In the past 5 years, Treace Medical Concepts' Assets ranged from a high of $251.9 million in Q4 2023 and a low of $37.4 million during Q1 2021
  • Its 5-year average for Assets is $188.3 million, with a median of $205.8 million in 2025.
  • Its Assets has fluctuated over the past 5 years, first soared by 29193.19% in 2022, then crashed by 1519.41% in 2025.
  • Over the past 5 years, Treace Medical Concepts' Assets (Quarter) stood at $140.8 million in 2021, then grew by 12.93% to $159.0 million in 2022, then surged by 58.41% to $251.9 million in 2023, then fell by 13.82% to $217.1 million in 2024, then fell by 9.44% to $196.6 million in 2025.
  • Its Assets stands at $196.6 million for Q3 2025, versus $206.4 million for Q2 2025 and $205.8 million for Q1 2025.